These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33038021)

  • 21. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome.
    Lam KW; Chow KW; Vo J; Hou W; Li H; Richman PS; Mallipattu SK; Skopicki HA; Singer AJ; Duong TQ
    J Infect Dis; 2020 Sep; 222(8):1256-1264. PubMed ID: 32702098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans.
    Derington CG; Cohen JB; Mohanty AF; Greene TH; Cook J; Ying J; Wei G; Herrick JS; Stevens VW; Jones BE; Wang L; Zheutlin AR; South AM; Hanff TC; Smith SM; Cooper-DeHoff RM; King JB; Alexander GC; Berlowitz DR; Ahmad FS; Penrod MJ; Hess R; Conroy MB; Fang JC; Rubin MA; Beddhu S; Cheung AK; Xian W; Weintraub WS; Bress AP
    PLoS One; 2021; 16(4):e0248080. PubMed ID: 33891615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does taking an angiotensin inhibitor increase the risk for COVID-19? - a systematic review and meta-analysis.
    Ma Z; Wang MP; Liu L; Yu S; Wu TR; Zhao L; Zhang YP; Liang HF; Yang XC
    Aging (Albany NY); 2021 Apr; 13(8):10853-10865. PubMed ID: 33886504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients.
    Genet B; Vidal JS; Cohen A; Boully C; Beunardeau M; Marine Harlé L; Gonçalves A; Boudali Y; Hernandorena I; Bailly H; Lenoir H; Piccoli M; Chahwakilian A; Kermanach L; de Jong L; Duron E; Girerd X; Hanon O
    J Am Med Dir Assoc; 2020 Nov; 21(11):1539-1545. PubMed ID: 33138935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of ACEi and ARB in COVID-19 management: A retrospective analysis.
    Kumar S; Nikravesh M; Chukwuemeka U; Randazzo M; Flores P; Choday P; Raja A; Aseri M; Shivang S; Chaudhuri S; Barve P
    Clin Cardiol; 2022 Jul; 45(7):759-766. PubMed ID: 35481554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers associated with lower risk of COVID-19 in household contacts.
    Armstrong K; Soltoff A; Rieu-Werden M; Metlay J; Haas J
    PLoS One; 2021; 16(3):e0247548. PubMed ID: 33651840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of RAAS inhibitors on acute hypoxemic respiratory failure and in-hospital mortality in the hypertensive Covid-19 patients.
    Akyüz A; Işık F; Aslan B; Çap M; Kaya İ; Atlı Ö; İnci Ü; Taştan E; Aktan A; Bilge Ö; Okşul M; Aydın E; Karahan Z; Altıntaş DD; Altındağ R; Adıyaman MŞ; Altıntaş B
    Clin Exp Hypertens; 2021 Oct; 43(7):587-596. PubMed ID: 33955313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis.
    Lo KB; Bhargav R; Salacup G; Pelayo J; Albano J; McCullough PA; Rangaswami J
    Expert Rev Cardiovasc Ther; 2020 Dec; 18(12):919-930. PubMed ID: 32945216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between RAAS Antagonism and COVID-19-related Mortality in Patients with Overweight/Obesity-related Hypertension: A Retrospective Cohort Study.
    Shams E; Kamalumpundi V; Cheng L; Taiwo A; Shibli-Rahhal A; Dokun AO; Correia MLG
    Arq Bras Cardiol; 2023 Mar; 120(4):e20220277. PubMed ID: 37098985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of ACEI and ARB on COVID-19 patients: A meta-analysis.
    Xue Y; Sun S; Cai J; Zeng L; Wang S; Wang S; Li J; Sun L; Huo J
    J Renin Angiotensin Aldosterone Syst; 2020; 21(4):1470320320981321. PubMed ID: 33325306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis.
    Hasan SS; Kow CS; Hadi MA; Zaidi STR; Merchant HA
    Am J Cardiovasc Drugs; 2020 Dec; 20(6):571-590. PubMed ID: 32918209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of renin-angiotensin-aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort study.
    Sato K; White N; Fanning JP; Obonyo N; Yamashita MH; Appadurai V; Ciullo A; May M; Worku ET; Helms L; Ohshimo S; Juzar DA; Suen JY; Bassi GL; Fraser JF; Arora RC;
    BMC Cardiovasc Disord; 2022 Mar; 22(1):123. PubMed ID: 35321649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertensive Patients with COVID-19 (COVIDECA Study).
    Mustafic H; Fayssoil A; Josseran L; Ouadahi M; Grimaldi-Bensouda L; Dubourg O; Annane D; Mansencal N
    Am J Cardiol; 2021 May; 147():58-60. PubMed ID: 33617818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis of the association between angiotensin pathway inhibitors and COVID-19 severity and mortality.
    Fernando ME; Drovandi A; Golledge J
    Syst Rev; 2021 Sep; 10(1):243. PubMed ID: 34488897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of the withdrawal of renin-angiotensin-aldosterone inhibitors on mortality in COVID-19 patients.
    Caro-Codón J; Rey JR; Iniesta AM; Rosillo SO; Castrejon-Castrejon S; Rodriguez-Sotelo L; Garcia-Veas JM; Marco I; Martinez LA; Martin-Polo L; Merino C; Martinez-Cossiani M; Buño A; Gonzalez-Valle L; Herrero A; López-de-Sá E; Merino JL;
    Rev Port Cardiol; 2022 Oct; 41(10):823-830. PubMed ID: 35784098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19.
    Rizk JG; Wenziger C; Tran D; Hashemi L; Moradi H; Streja E; Ahluwalia A
    Drugs; 2022 Jan; 82(1):43-54. PubMed ID: 34914085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
    Cochrane Database Syst Rev; 2009 Jul; (3):CD007004. PubMed ID: 19588415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.